UK clinical trials - updated daily from ClinicalTrials.gov
Find clinical trials for Alzheimer's disease and other dementias in the United Kingdom. Explore treatment pathways including disease-modifying therapies and symptomatic treatments.
Alzheimer's disease is the most common cause of dementia, affecting ~850,000 people in the UK (projected to reach 1.6 million by 2040). It causes progressive memory loss, confusion, and changes in behaviour. While there is currently no cure, recent breakthroughs in anti-amyloid therapies are showing promise in slowing disease progression, particularly when started early.
Anti-amyloid antibodies represent the first disease-modifying treatments: lecanemab (Leqembi) slows cognitive decline by ~27% in early Alzheimer's by clearing amyloid plaques. Donanemab showed similar benefits. These are approved in the US and under review by the MHRA/NICE in the UK. Eligibility requires amyloid confirmation (PET scan or lumbar puncture) and early-stage disease (MCI or mild dementia). Risk of ARIA (brain swelling/bleeding) requires regular MRI monitoring.
Symptomatic treatments: donepezil, rivastigmine, galantamine (cholinesterase inhibitors) for mild-moderate Alzheimer's. Memantine (NMDA receptor antagonist) for moderate-severe disease. Non-drug approaches: cognitive stimulation therapy, exercise, social engagement, and carer support. For behavioural symptoms: antipsychotics should be avoided where possible; person-centred care, music therapy, and environmental modifications are preferred.
Active UK dementia trials include: anti-tau therapies, anti-amyloid combinations, neuroinflammation modulators, gut-brain axis interventions, digital biomarkers for early detection, blood tests for amyloid/tau, precision medicine approaches, and prevention trials for at-risk individuals. Join Dementia Research is the UK's national registry for dementia study volunteers.
Free AI-powered matching - no signup required
Search Alzheimer's disease Trials →